Insulet said it achieved record new customer starts in the fourth quarter and for the full year across the U.S., international markets, and company-wide. CFO Flavia Pease noted that in the U.S. during the fourth quarter, more than 85% of new customer starts came from people transitioning from multiple daily injections (MDI), and type 2 represented more than 40% of all starts.For the full year, the company reported revenue of more than $2.7 billion , up 29.5% constant currency (30.7% reported). Management sa ...

Medtronic PLC (NYSE:MDT) posted better-than-expected earnings for the third quarter on Tuesday.The company posted adjusted EPS of $1.36, beating market estimates of $1.33. The company’s quarterly sales came in at $9.017 billion, versus expectations of $8.905 billion.Medtronic affirmed its FY2026 adjusted EPS guidance of $5.62-$5.66, versus market estimates of $5.65.Medtronic shares rose 0.1% to $96.45 in pre-market trading.These analysts made changes to their price targets on Medtronic following earnings an ...

Financial Data and Key Metrics Changes - The company closed 2025 with total revenues of $784 million in Q4, representing a 29% increase in constant currency and a 31.2% increase at reported rates [7][26] - Full year revenues surpassed $2.7 billion, more than doubling the revenue base over the last three years, with approximately 30% year-over-year constant currency growth [7][26] - Adjusted EPS for Q4 was $1.55, a 35% increase from $1.15 in the prior year, while full year adjusted EPS was $4.97, up 53% from $3.24 [33] Business Line Data and Key Metrics Changes - U.S. revenues for Omnipod grew 28% in Q4 and 27.2% for the full year, driven by demand across Type 1 and Type 2 customers [27] - International Omnipod revenue grew 50.7% on a reported basis and 41.7% on a constant currency basis for Q4, with full year growth at 44.1% reported and 39.3% constant currency [28] - The company achieved record new customer starts across both U.S. and international markets, with over 85% of new starts in the U.S. coming from multiple daily injections [27][8] Market Data and Key Metrics Changes - The U.S. Type 1 market is valued at over $9 billion, with AID penetration at just 40%, indicating significant growth potential [9] - The Type 2 market exceeds $12 billion, with AID penetration below 5%, presenting a substantial opportunity for expansion [11] - The company has established a prescriber base of over 30,000 healthcare professionals in the U.S., up approximately 28% year-over-year [9] Company Strategy and Development Direction - The company aims to maintain its leadership position in the AID market while expanding its customer base, particularly in Type 2 diabetes [8][10] - A fully closed loop offering is planned for launch in 2028, which is expected to enhance accessibility for Type 2 diabetes patients [12][21] - Continued investment in R&D is prioritized, with plans to increase spending significantly to support innovation and market expansion [30][72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain top-tier growth and margin expansion, supported by a strong financial position and recurring revenue model [16][71] - The company anticipates total Omnipod revenue growth of 21%-23% and total company revenue growth of 20%-22% for 2026, reflecting continued market leadership [36][37] - Management highlighted the importance of educating healthcare providers on the clinical performance of Omnipod to drive further adoption [55][68] Other Important Information - The company ended 2025 with $760 million in cash and $500 million available under its credit facility, delivering over $375 million in free cash flow for the year [34] - The company has expanded its global footprint with launches in nine new countries and plans to enter Spain by late 2026 [14][37] Q&A Session Summary Question: Insights on underappreciated aspects of Insulet - Management highlighted four key areas: technology leadership, growing commercial prowess, manufacturing at scale, and financial strength [45][49] Question: Trends in new patient starts in the U.S. and internationally - The company reported record new customer starts in both markets, primarily driven by patients transitioning from multiple daily injections [53][54] Question: Reconciling script trends with reported revenue - Management advised that total pods are the best reflection of future revenue outlook, with script data being a secondary option [61] Question: Sustaining growth amid competition - Management emphasized barriers to entry for competitors, including manufacturing at scale and the need for strong clinical performance [68][70]

Financial Data and Key Metrics Changes - The company closed 2025 with total revenues of $784 million in Q4, representing a 29% increase in constant currency and a 31.2% increase at reported rates [7][26] - Full year revenues surpassed $2.7 billion, more than doubling the revenue base over the last three years, with approximately 30% year-over-year constant currency growth [7][26] - Adjusted EPS for Q4 was $1.55, a 35% increase from $1.15 in the prior year, while full year adjusted EPS was $4.97, up 53% from $3.24 [33] Business Line Data and Key Metrics Changes - U.S. revenues for Omnipod grew 28% in Q4 and 27.2% for the full year, driven by demand for Omnipod 5 across Type 1 and Type 2 customers [27] - International Omnipod revenue grew 50.7% on a reported basis and 41.7% on a constant currency basis for Q4, with full year growth at 44.1% reported and 39.3% constant currency [28] - Record new customer starts were achieved across both U.S. and international markets, with over 85% of new customer starts in the U.S. coming from multiple daily injections (MDI) [27][8] Market Data and Key Metrics Changes - The U.S. Type 1 market is valued at over $9 billion, with AID penetration at just 40%, indicating significant growth potential [9] - The Type 2 market exceeds $12 billion, with AID penetration below 5%, presenting a substantial opportunity for growth [11] - The company has expanded its prescriber base to over 30,000 healthcare professionals in the U.S., a 28% increase year-over-year [9] Company Strategy and Development Direction - The company aims to maintain its leadership position in the automated insulin delivery (AID) market, focusing on expanding penetration in both Type 1 and Type 2 diabetes segments [8][9] - Plans include launching a fully closed loop system for Type 2 diabetes by 2028, which is expected to significantly increase market access [12][21] - Continued investment in R&D is prioritized, with a commitment to deliver innovative enhancements and maintain competitive advantages [19][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain top-tier growth and value creation for shareholders, supported by a strong financial position and operational excellence [16][24] - The company anticipates total Omnipod revenue growth of 21%-23% and total company revenue growth of 20%-22% for 2026, reflecting continued market-leading growth [35][36] - Management acknowledged potential challenges in growth deceleration due to anniversarying the first full year of the U.S. launch of Omnipod for Type 2 and annualizing international launches [36] Other Important Information - The company ended 2025 with $760 million in cash and $500 million available under its credit facility, delivering over $375 million in free cash flow for the year [34] - The company has a strong commitment to reducing barriers to access for patients, with broad market access available in approximately 48,000 U.S. pharmacies [13] Q&A Session All Questions and Answers Question: What is the most underappreciated part of the Insulet story from an investor perspective? - Management highlighted four key areas: technology leadership, growing commercial prowess, manufacturing at scale, and financial strength [45][49] Question: How are you thinking about sustaining new patient growth in the U.S. and internationally? - Management noted balanced growth from both U.S. and international markets, with a primary source of volume coming from patients transitioning from MDI [53][54] Question: Can you help reconcile script trends to reported revenue? - Management advised that total pods are the best reflection of future revenue outlook, with total scripts as a secondary option [60] Question: How do you feel about sustaining 20% growth in light of new competition? - Management emphasized barriers to entry in the market, including manufacturing at scale and the need for continued innovation [66][70]

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Picard Medical, Inc.(PMI) Shareholders [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Picard Medical, Inc. ("Picard Medical, Inc." or the "Company") (NYSE: PMI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Picard Medical, Inc. investors who were adversely affected by alleged securities fraud be ...

Core Viewpoint - Tenon Medical, Inc. is enhancing its competitive position and supporting its long-term growth strategy through a strategic expansion of its U.S. intellectual property portfolio, following the receipt of Notices of Allowance for multiple patent applications expected to issue in 2026 [1] Group 1: Intellectual Property Expansion - The company has received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for multiple patent applications [1] - This expansion will strengthen the company's growing patent portfolio, building upon the ten patents issued in 2025, which includes five issued by the USPTO and five issued internationally [1]

Core Insights - Inspira Technologies has initiated a structured commercial evaluation of its FDA-cleared INSPIRA™ ART100 system at a leading U.S. academic medical center, expanding its presence in the Tier-1 U.S. hospital market [1][3] Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions [5] - The INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., serving as a foundation for the development of the next-generation INSPIRA ART500 system [5] - The company is also advancing the HYLA™ platform, a proprietary blood sensor offering continuous, non-invasive monitoring [5] Market Positioning - The deployment of the ART100 system is part of the company's U.S. commercial strategy, aiming to convert high-profile evaluations into a sustainable commercial pipeline [4] - The partnering institution is ranked among New York State's top 10 hospitals, indicating the ART100's alignment with the operational and clinical demands of top-tier U.S. healthcare providers [2][4]

Achieved $100.3 million in 2025 net sales, representing 54% year-over-year growth driven by a doubling of the installed base to 35,000 users. Attributed sales force productivity to the iLet's fully automated algorithm and digital ecosystem, which allowed a smaller team of 63 territories to compete effectively against larger incumbents. Successfully executed a pharmacy channel strategy, establishing formulary agreements with all major U.S. PBMs to lower patient out-of-pocket costs and drive high-margin ...

Performance overperformance in Q4 was driven by the simultaneous maturation of investments in sales personnel, CRM technology, and refined go-to-market processes. The sales force reached a strategic 1:1 ratio of account managers to product specialists, optimizing the balance between clinical selling and complex order support. Lymphedema growth was bolstered by the new National Coverage Determination (NCD), allowing eligible Medicare patients to access advanced Flexitouch pumps without first failing ba ...

Core Insights - SINTX Technologies has appointed Ryan Elmore as President, effective March 16, 2026, to accelerate revenue opportunities from its SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies [1][3]. Company Strategy - Mr. Elmore will lead the transition of SINTX from a product-focused medical device manufacturer to a broader biomaterials platform company, leveraging its proprietary silicon nitride expertise and expanding intellectual property portfolio [3][5]. - The company aims to commercialize silicon nitride technologies across various product categories, including sutures, mesh, and wound dressings, while expanding its capabilities to support multiple material forms [4][5]. Leadership Background - Ryan Elmore brings over 15 years of experience in advanced biomaterials and medical device commercialization, previously serving as Core Business Director at Invibio, a division of Victrex plc [2][5]. - His mandate includes implementing a disciplined commercial execution strategy to translate SINTX's platform assets into scalable revenue opportunities [5]. Product Development Focus - SINTX is focused on expanding the adoption of SiNERGY™ SiN/PEEK biocomposites and developing new product formats such as filament, rod, and sheet to support various manufacturing workflows [4][5]. - The company has established itself as a leader in high-performance biomaterials, with thousands of medical devices implanted since 2008 and a strong patent portfolio [8].